Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and...
Overview
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul><li><em>Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics </em></li><li><em>Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and...
Source
Originally published at markets.businessinsider.com.
